Search

Displaying results 7611 - 7620 of 10000 in total
  1. Drug

    Tricetin

    go.drugbank.com/drugs/DB08230
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Pimobendan

    go.drugbank.com/drugs/DB11450
    ExperimentalVet approved

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Ammonium tetrathiomolybdate

    go.drugbank.com/drugs/DB17641
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Uridine monophosphate

    go.drugbank.com/drugs/DB03685
    Investigational

    A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.

  5. Drug

    AUTO3

    go.drugbank.com/drugs/DB17364
    Investigational

    AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL). … It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.

  6. Drug

    Lofentanil

    go.drugbank.com/drugs/DB09174
    ExperimentalIllicit

    It displays most similarity to carfentanil (4-carbomethoxyfentanyl) and is considered to be slightly more potent than this drug. … Lofentanil is an analog of fentanyl and is one of the most potent opioids available today.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Dexetimide

    go.drugbank.com/drugs/DB08997
    ApprovedWithdrawn

    A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.

  8. Drug

    Hycanthone

    go.drugbank.com/drugs/DB14061
    Experimental

    Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.

  9. Drug

    RLYB212

    go.drugbank.com/drugs/DB17727
    Investigational

    RLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.

  10. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody.[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

    Synonyms: MAB HUMAN (IGG4) ANTI P01137 (TGFB1_HUMAN) OR ANTI P61812 (TFGB2_HUMAN) OR ANTI P10600 (TGFB3_HUMAN)(SAR439459)